An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer
Latest Information Update: 20 Mar 2025
At a glance
- Drugs Afuresertib (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROFECTA-II
- Sponsors Laekna Therapeutics
Most Recent Events
- 19 Aug 2024 Status changed from active, no longer recruiting to completed.
- 11 Mar 2024 Planned End Date changed from 25 Nov 2024 to 28 Jun 2024.
- 12 Dec 2023 Planned End Date changed from 25 Sep 2023 to 25 Nov 2024.